OncoTargets and Therapy · 2016 · 47 citations · 34 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaThoracic OncologyCancer BiomarkersCancer Molecular PathologyLung CancerMolecular Classification Of TumorsTumor AntigensTumor-associated AntigensExcision Repair Cross-complementation Group 1Immunohistochemical BiomarkersImmunohistochemical MarkersImmunohistochemical StainingInvasive Mucinous AdenocarcinomaLung AdenocarcinomaPrognostic BiomarkersTumor-specific Biomarkers
Background: We performed an analysis to clarify differences in clinicopathological and molecular features of lung invasive mucinous adenocarcinoma (IMA) based on computed tomography (CT) findings and their impact on prognosis. Patients and methods: On the basis of CT findings, we divided lung IMA into three subtypes: solid, bubbling, and pneumonic. We then investigated differences in clinicopathological characteristics, prognosis, and the expressions of well-identified biomarkers, including cyclooxygenase-2 (Cox-2), excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), class III beta-tubulin, thymidylate synthase (TS), secreted protein acidic and rich in cysteine (SPARC), programmed cell death-1 ligand-1 (PD-L1), and epidermal growth factor receptor mutation, among the three subtypes. Results: A total of 29 patients with resected lung IMA were analyzed. Compared with the solid or bubbling type, the pneumonic type had a higher proportion of symptoms, a larger tumor size, a higher pathological stage, and a significantly worse prognosis. The immunohistochemical findings tended to show high expression of RRM1, class III beta-tubulin, and Cox-2 in the tumor and of SPARC in the stroma, but not of ERCC1, TS, and PD-L1 in the tumor. None of the biomarkers with high expression levels in the tumor were prognostic biomarkers, but the expression of SPARC in the stroma was correlated with a poor outcome. Conclusion: Clinical and pathological features, in conjunction with molecular data, indicate that IMA should be divided into different subgroups. In our results, the pneumonic type was correlated with a significantly worse outcome. Further studies should be performed to confirm our conclusion and to explore its molecular implications. Keywords: non-small cell lung cancer, invasive mucinous adenocarcinoma, computed tomography finding, prognostic biomarker, secreted protein acidic and rich in cysteine, SPARC
34
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Akihiko Yoshizawa, Noriko Motoi, Gregory J. Riely et al. · Modern Pathology · 2011 · 994 citations · Full text
Arne Warth, Thomas Muley, Michael Meister et al. · Journal of Clinical Oncology · 2012 · 703 citations